Leon Recanati, a director of Evogene Ltd. (EVGN), received an award of 2,500 stock options on September 4, 2026, according to a Form 4 summary from the SEC. The transaction is described as an award or grant of options carrying a right to buy stock.

The supplied SEC item was published on September 30, 2026, at 12:13 UTC. That publication timestamp is separate from the reported transaction date. The summary does not independently identify the filing submission date, so September 30 should not be treated as a confirmed filing date.

What the disclosure reports

The reported recipient is Recanati, whose role at Evogene is listed as director. The amount is 2,500 stock options, and the transaction classification is an award or grant. The summary also indicates that the transaction was not made under a Rule 10b5-1 plan.

Those details describe an option award. They do not establish that Recanati purchased shares in the market, exercised the options or sold any stock. The option count should therefore be read as the size of the reported grant, rather than as a disclosed cash investment or sale proceeds.

What remains unspecified

The supplied material does not provide an exercise price, expiration date, vesting schedule or monetary valuation for the award. It also does not state Recanati’s total holdings following the transaction or explain the company’s reason for making the grant.

Analysis: The disclosure provides a limited view of an equity award to a company director. Without the award terms or broader ownership information, it does not support a conclusion about the grant’s financial value, its effect on ownership percentages or Recanati’s expectations for Evogene’s share price.

What to watch

The full filing would be the place to check the submission date and any disclosed exercise price, vesting conditions, expiration date or ownership information. Until those details are available, the supported account remains a grant of 2,500 stock options dated September 4.